Fish-derived bioactive peptide compositions for antiplatelet therapy, their preparation methods and applications
By preparing and compounding specific sequence active peptides from the gills, skin, and flesh of the Chinese gudgeon, targeting the P2Y12 receptor, the problem of unclear active peptide sequences and poor quality stability in existing technologies has been solved. This has achieved highly efficient inhibition of platelet aggregation and antithrombosis, and has good prospects for industrial application and safety.
Patent Information
- Application Number
- CN202611496582.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-24
- Publication Date
- 2026-11-17
AI Technical Summary
Existing research on fish-derived antiplatelet bioactive peptides mostly focuses on single tissue sources, resulting in unclear bioactive peptide sequences, poor quality stability, and difficulty in fully leveraging the functional advantages of different protein sources. Furthermore, existing antiplatelet drugs have safety concerns regarding long-term use.
By utilizing different types of protein resources from the gills, skin, and flesh of the Chinese gudgeon, and employing differentiated enzymatic hydrolysis and targeted separation and purification strategies, five specific sequence active peptides, G1, P1, P2, M1, and M2, were prepared and compounded in a specific ratio to form an antiplatelet fish-derived active peptide composition. This composition targets the P2Y12 receptor to exert antiplatelet aggregation and antithrombotic effects.
This study has enabled the high-value utilization of low-value aquatic resources of the Chinese sturgeon. The obtained active peptide composition has a clear amino acid sequence and structure, good quality controllability, and can effectively inhibit platelet activation and aggregation, reduce the risk of bleeding, and is suitable as an antithrombotic component in drugs and functional foods.
Smart Images

Figure CN123106830A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedicine and functional food technology, specifically relating to an antiplatelet fish-derived active peptide composition and its preparation method, particularly relating to a composition in which the active ingredients are composed of five specific sequence active peptides derived from different tissues of the Chinese bream (Uranoscopus chinensis) in a specific ratio, and its application in the preparation of products that inhibit platelet aggregation and prevent thrombosis. Background Technology
[0002] Platelets are essential cellular components for maintaining normal hemostasis. When vascular endothelium is damaged, platelets can rapidly adhere, activate, and aggregate, forming hemostatic thrombi to maintain vascular integrity. However, under pathological conditions such as atherosclerosis, hypertension, hyperlipidemia, diabetes, and chronic inflammation, platelets are prone to abnormal activation and excessive aggregation, leading to pathological thrombi. Pathological thrombi are a significant contributing factor to cardiovascular and cerebrovascular diseases such as myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism. Therefore, developing safe and effective antiplatelet active substances has always been an important research direction in the fields of functional foods and biomedicine.
[0003] Currently, commonly used antiplatelet drugs in clinical practice mainly include aspirin, clopidogrel, and ticagrelor, which exert antithrombotic effects by inhibiting platelet activation signaling pathways. However, long-term use of these drugs may lead to problems such as gastrointestinal damage, increased bleeding risk, drug tolerance, and individual variability in response. Therefore, it is of great significance to find antiplatelet active ingredients that are naturally derived, highly safe, and suitable for long-term intake.
[0004] In recent years, bioactive peptides have attracted widespread attention due to their small molecular weight, good biocompatibility, easy absorption and utilization, low toxicity, and ability to exert biological activity through multiple targets. Numerous studies have shown that small-molecule bioactive peptides produced by targeted enzymatic hydrolysis of proteins can exhibit various physiological functions, including antioxidant, antihypertensive, lipid metabolism regulation, immunomodulation, and antithrombotic effects. Among these, natural bioactive peptides derived from food proteins have good food safety and promising prospects for industrial application, making them an important research direction in the fields of functional foods and special medical foods.
[0005] Marine fish are rich in protein resources with a balanced amino acid composition, especially rich in key amino acids required for the formation of bioactive peptides, such as lysine, arginine, glycine, and proline, making them an important source of natural bioactive peptides. Compared with some terrestrial animal proteins, fish proteins have a relatively loose structure and lower connective tissue content, making them more readily released into short peptide fragments with specific physiological activities through enzymatic decomposition. In recent years, bioactive peptides obtained from marine fish such as cod, salmon, and tuna have been proven to possess antioxidant, antihypertensive, and antithrombotic biological activities, showing good development potential.
[0006] The Chinese sturgeon (Uranoscopus chinensis), belonging to the family Uranoscopus, is a marine economic fish widely distributed in the Yellow Sea, East China Sea, and South China Sea of my country. Its resources are abundant and its acquisition cost is relatively low, providing a good foundation for industrial development. However, due to its relatively limited economic value, processing often only retains a portion of the edible flesh, while the utilization rate of by-products such as skin, gills, and scraps is low, resulting in a significant waste of high-quality protein resources. In fact, the skin of the Chinese sturgeon is rich in collagen, the flesh is rich in myofibrillar and sarcoplasmic proteins, and the gills contain abundant structural proteins and mucus-related proteins. These different tissues exhibit significantly different protein compositions, providing a good material basis for obtaining structurally diverse and functionally complementary bioactive peptides.
[0007] However, most existing research on fish-derived antiplatelet bioactive peptides focuses on the enzymatic hydrolysis products of proteins from single tissues. The resulting components are usually quite complex, with problems such as unclear bioactive peptide sequences, poor quality stability, and difficulty in controlling the active ingredients. At the same time, research on differentiated enzymatic hydrolysis, targeted screening, and construction of synergistic bioactive peptide combinations targeting proteins from different fish tissues is still relatively insufficient, making it difficult to fully utilize the functional advantages of different protein sources.
[0008] Therefore, it is necessary to develop an antiplatelet active peptide composition based on different tissue protein resources of the Chinese gill and its preparation method. By utilizing protein resources from the gills, skin, and flesh of the fish, and employing differentiated enzymatic hydrolysis and targeted separation and purification strategies, structurally well-defined small-molecule active peptides can be obtained. Furthermore, a polypeptide combination system with controllable composition, stable quality, and good antiplatelet activity can be constructed, thereby realizing the high-value utilization of Chinese gill resources and providing a new technical approach for the development of natural antithrombotic functional products. Summary of the Invention
[0009] To address the shortcomings of existing technologies, this invention provides a fish-derived active peptide composition for antiplatelet therapy, its preparation method, and its application.
[0010] To achieve the above objectives, the present invention adopts the following technical solution:
[0011] In a first aspect, the present invention provides a compound active peptide composed of five active peptides derived from different tissues of the Chinese bream (Uranoscopus chinensis);
[0012] The five active peptides are as follows:
[0013] (1) Fish gill-derived bioactive peptide G1, the amino acid sequence of which is RLPGDFR (SEQ ID NO.1), and the molecular weight of the bioactive peptide G1 is 850-900 Da;
[0014] (2) Fish skin-derived active peptide P1, whose amino acid sequence is GEPGPRG (SEQ ID NO.2), and the molecular weight of the active peptide P1 is 620-680 Da;
[0015] (3) Fish skin-derived active peptide P2, the amino acid sequence of which is DGEPGPA (SEQ ID NO.3), and the molecular weight of the active peptide P2 is 600-660 Da;
[0016] (4) Fish-derived bioactive peptide M1, whose amino acid sequence is QNWPFR (SEQ ID NO.4), and whose molecular weight is 820-850 Da;
[0017] (5) Fish-derived bioactive peptide M2, the amino acid sequence of which is VQGDFPR (SEQ ID NO.5), and the molecular weight of the bioactive peptide M2 is 790-850 Da.
[0018] Preferably, the mass ratio of the active peptides G1, P1, P2, M1 and M2 is 1:(2-4):(2-4):(1-3):(1-3), more preferably 1:3:3:2:2.
[0019] Secondly, the present invention provides a method for preparing the above-mentioned complex active peptides, comprising the following steps:
[0020] 1) Pre-treatment: The gills, skin and meat of the Chinese mackerel are cleaned, degreased and crushed respectively for pre-treatment.
[0021] Preferably, the degreasing in step 1) is performed by ethanol extraction with a volume fraction of 90-95%, the material-to-liquid ratio (g:mL) is 1:(5-10), the treatment temperature is 25-45℃, and the treatment time is 1-3h.
[0022] 2) Enzymatic hydrolysis: The pretreated fish gills, fish skin and fish meat were enzymatically hydrolyzed separately to obtain fish gill hydrolysate, fish skin hydrolysate and fish meat hydrolysate.
[0023] Preferably, in step 2), the fish gills are hydrolyzed using papain at a concentration of 3000–4000 U / g substrate, with a pH of 6.5–7.0, a temperature of 50–60°C, and a hydrolysis time of 3–5 hours; the fish skin is hydrolyzed using a combination of collagenase and flavor protease at a concentration of 1500–2500 U / g substrate and 2000–3000 U / g substrate, with a temperature of 45–55°C and a hydrolysis time of 5–8 hours; and the fish meat is hydrolyzed using a combination of trypsin and alkaline protease at a concentration of 2500–3500 U / g substrate and 1500–2500 U / g substrate, with a temperature of 40–50°C and a hydrolysis time of 4–6 hours.
[0024] 3) Enzyme inactivation centrifugation: Heat each enzyme hydrolysate to inactivate the enzyme, centrifuge, and collect the supernatant.
[0025] Preferably, the enzyme inactivation temperature in step (3) is 95°C and the enzyme inactivation time is 10-15 min; the centrifugation conditions are 4°C, 10000 rpm, and centrifugation for 15-20 min.
[0026] 4) Ultrafiltration: Ultrafiltration is performed on each supernatant to collect the permeate with a molecular weight of less than 3 kDa.
[0027] Preferably, the ultrafiltration in step 4) is performed by sequentially using ultrafiltration membranes with molecular weight cutoffs of 10kDa, 5kDa and 3kDa for graded ultrafiltration.
[0028] 5) Chromatographic purification and mass spectrometry identification: The permeate obtained in step 4) was purified by chromatography. The components were collected according to the chromatographic elution peaks and identified by liquid chromatography-tandem mass spectrometry (LC-MS / MS) as active peptides G1, P1, P2, M1 and M2 with amino acid sequences as shown in SEQ ID NO. 1 to 5.
[0029] Preferably, the chromatographic purification includes gel chromatography and reversed-phase high-performance liquid chromatography. Wherein:
[0030] The gel chromatography was performed using a Sephadex G-25 dextran gel chromatography column (90 cm long, 1.5 cm inner diameter), eluted with 20 mmol / L Tris-HCl buffer (pH 7.4), at a flow rate of 1.0 mL / min, and detected at a wavelength of 220 nm. Each elution peak was collected according to the elution curve.
[0031] The reversed-phase high-performance liquid chromatography (RP-HPLC) used a C18 column (4.6 mm × 250 mm, 5 μm). Mobile phase A was ultrapure water containing 0.1% trifluoroacetic acid (TFA), and mobile phase B was acetonitrile containing 0.1% trifluoroacetic acid. The gradient elution program was as follows: 0–5 min, 5% B; 5–40 min, 5%–40% B; 40–45 min, 40%–95% B; 45–50 min, 95% B; 50–55 min, 95%–5% B. The flow rate was 1.0 mL / min, and the detection wavelength was 220 nm.
[0032] Preferably, in the liquid chromatography-tandem mass spectrometry identification, the primary mass spectrometry scanning range is 100–1500 m / z, and the secondary mass spectrometry scanning range is 50–1500 m / z. The amino acid sequence is analyzed and confirmed based on the fragment ion (b ion, y ion) information from the secondary mass spectrometry.
[0033] 6) Mixing: Mix the five active peptides collected in step 5) in proportion to obtain the final product.
[0034] Preferably, the five active peptides G1, P1, P2, M1 and M2 described in step 6) are mixed in a mass ratio of 1:3:3:2:2.
[0035] Thirdly, the present invention provides a fish-derived active peptide composition for antiplatelet therapy, comprising an active ingredient and pharmaceutically or food-grade acceptable excipients; wherein the active ingredient is the aforementioned compound active peptide.
[0036] Preferably, the excipients are selected from one or more of maltodextrin, microcrystalline cellulose, hydroxypropyl methylcellulose, lactose, mannitol, gum arabic, polyvinylpyrrolidone, sodium carboxymethyl cellulose, magnesium stearate, silicon dioxide, sodium citrate, vitamin C, potassium sorbate, citric acid, and water.
[0037] Preferably, the dosage form of the composition is one of tablets, capsules, granules, oral liquid, lyophilized powder, or solid beverage.
[0038] Fourthly, the present invention provides a method for preparing the above-mentioned antiplatelet fish-derived active peptide composition, comprising the following steps:
[0039] I. Prepare the compound active peptides according to steps 1)-6) above;
[0040] 2. The compounded active peptide is mixed evenly with pharmaceutically or food-grade acceptable excipients and then dried to obtain the composition.
[0041] Fifthly, the present invention provides the use of the above-mentioned compound active peptide or antiplatelet fish-derived active peptide composition in the preparation of drugs or functional foods for inhibiting platelet aggregation and / or preventing thrombosis.
[0042] The antiplatelet fish-derived active peptide composition of the present invention exerts its antiplatelet aggregation and antithrombotic effects by specifically targeting the P2Y12 receptor.
[0043] The specific mechanism of action is as follows: the active peptide in the composition can bind to the P2Y12 receptor on the platelet surface, exerting an antagonistic effect and blocking the activation of the P2Y12 receptor by ADP. After the P2Y12 receptor is inhibited, on the one hand, the activation of phosphatidylinositol 3-kinase (PI3K) mediated by Gβγ protein is blocked, thereby inhibiting the phosphorylation of downstream protein kinase B (Akt), reducing the release of dense granules and the increase in intracellular calcium ion levels; on the other hand, the inactivation of the P2Y12 receptor relieves the inhibition of adenylate cyclase, restoring the level of cyclic adenosine monophosphate (cAMP), thereby maintaining the phosphorylation state of vasodilatory stimulating phosphoprotein (VASP), further inhibiting platelet activation and aggregation.
[0044] The regulation of the aforementioned dual signaling pathways ultimately inhibits the inside-out conformational activation of the glycoprotein IIb / IIIa (GPIIb / IIIa) receptor, preventing fibrinogen from binding to GPIIb / IIIa, thereby inhibiting platelet aggregation.
[0045] Unlike traditional GPR series antiplatelet peptides that act directly on the GPIIb / IIIa final pathway, the composition of this invention acts on the upstream target of the P2Y12 receptor. While effectively inhibiting ADP-induced platelet aggregation, it does not interfere with the coagulation cascade reaction, does not affect prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT), and does not prolong bleeding time. The bleeding risk is significantly lower than that of existing GPR series peptides and clinical antiplatelet drugs.
[0046] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0047] 1) This invention is the first to make full use of different types of protein resources in the gills, skin and flesh of the Chinese gudgeon. Through differentiated enzymatic hydrolysis, directional separation and sequence identification, active peptide components with clear sources and structures are obtained, realizing the high-value utilization of low-value aquatic resources and processing by-products of the Chinese gudgeon, improving resource utilization rate and product added value, and has good prospects for industrial application.
[0048] 2) The five active peptides obtained by this invention all have clear amino acid sequences and reproducible molecular structures. Compared with fish protein hydrolysates, crude extracts of active peptides or molecular weight range components commonly found in the prior art, the active ingredients of this invention are clear, the quality is controllable, and the batch stability is high, which is conducive to standardized production and quality control of the product.
[0049] 3) This invention uses a scientific combination of fish gill-derived active peptide G1, fish skin-derived active peptides P1 and P2, and fish meat-derived active peptides M1 and M2. The active peptides from different sources form a synergistic effect in the antiplatelet process. Compared with a single active peptide, it can more effectively inhibit platelet activation and aggregation, improve antithrombotic activity, and thus obtain more stable and significant biological effects.
[0050] 4) The active peptide composition of this invention works by targeting the platelet P2Y12 receptor, blocking ADP-mediated platelet activation signaling. On one hand, it inhibits the activation of the downstream PI3K / Akt signaling pathway of the P2Y12 receptor, reducing intracellular calcium ion levels and dense granule release; on the other hand, it restores adenylate cyclase activity, increases intracellular cAMP levels, and maintains VASP phosphorylation, thereby jointly inhibiting the platelet activation process. Ultimately, by inhibiting the conformational activation of the GPIIb / IIIa receptor, it blocks the binding of fibrinogen to the platelet surface, achieving effective inhibition of platelet aggregation and thrombus formation.
[0051] 5) Compared with existing antiplatelet peptides such as the GPR series and RGD series that directly act on the GPIIb / IIIa terminal receptor, the composition of the present invention acts on the upstream regulatory target of the ADP-P2Y12 signaling axis. While effectively inhibiting platelet aggregation, it does not directly interfere with the coagulation cascade reaction and does not significantly affect prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT). Therefore, it has a lower bleeding risk and better long-term safety, and is more suitable as an antithrombotic active ingredient in drugs, health foods, and functional foods.
[0052] 6) The composition of the present invention is derived from natural sources, the preparation process is simple, the raw materials used are widely available and low in cost, and the resulting active peptides have good water solubility, biocompatibility and oral application potential, and can be widely used in the development of antiplatelet, antithrombotic and cardiovascular health products. Attached Figure Description
[0053] Figure 1 This is a bar chart comparing the maximum aggregation rate of ADP-induced rat platelets in each group of samples in Experiment 1 of this invention.
[0054] Figure 2 This is a graph showing the effect of each group of samples in Experiment 2 of this invention on the activation level of platelet GPIIb / IIIa receptors detected by PAC-1 flow cytometry; where, Figure 2 A is a scatter plot of flow cytometry findings. Figure 2 B is a bar chart showing the positive rate of PAC-1;
[0055] Figure 3 This is a graph showing the effect of each group of samples in Experiment 3 of this invention on the degree of platelet particle release detected by CD62P (P-selectin) flow cytometry; among them, Figure 3 A is a scatter plot of flow cytometry findings. Figure 3 B is a bar chart comparing the positive rates of CD62P expression;
[0056] Figure 4 This is a bar chart comparing the time to complete blood flow occlusion in the FeCl3-induced rat carotid artery thrombosis model of each group of samples in Experiment 4 of this invention.
[0057] Figure 5 This is a bar chart comparing the effects of each group of samples in Experiment 5 of this invention on rat coagulation function indicators (PT, APTT, TT);
[0058] Figure 6 This is a bar chart comparing the effects of each group of samples on the tail bleeding time of rats in Experiment 6 of this invention;
[0059] Figure 7This is a map showing the effects of each group of samples in Experiment 7 of this invention on the expression and phosphorylation levels of key proteins in the PI3K / Akt signaling pathway in platelets; among them, Figure 7 A is a Western blotting image of protein bands. Figure 7 B is a bar chart comparing the grayscale ratios of p-PI3K / PI3K and p-Akt / Akt;
[0060] Figure 8 This is a graph showing the effect of each group of samples in Experiment 8 of this invention on the phosphorylation level of VASP protein in platelets; among them, Figure 8 A is a Western blotting image of protein bands. Figure 8 B is a bar chart comparing the p-VASP / VASP grayscale ratio;
[0061] Figure 9 The images show the gel electrophoresis results of the active peptides and the primary mass spectra of the five active peptides obtained by LC-MS / MS detection. The characteristic peaks marked in the primary mass spectra represent the characteristic mass-to-charge ratios of the corresponding active peptides.
[0062] Figure 10 This is a schematic diagram of reversed-phase HPLC-MS analysis of the bioactive peptide G1.
[0063] Figure 11 This is a schematic diagram illustrating the separation and purification of bioactive peptides P1 and P2.
[0064] Figure 12 This is a schematic diagram illustrating the separation and purification of bioactive peptides M1 and M2.
[0065] Figure 13 This is the overall mass spectrometry characterization of the five active peptide compositions;
[0066] Figure 14 This is a comparison of actual blood clot retraction in different groups during the antiplatelet experiment. Detailed Implementation
[0067] The present invention will be further described below through specific embodiments. To make the inventive objectives, technical solutions, and beneficial technical effects of the present invention clearer, the present invention will be further described in detail below with reference to the embodiments. It should be understood that the embodiments described in this specification are merely for explaining the present invention and are not intended to limit the present invention.
[0068] Unless otherwise stated, all instruments and reagents used in the examples are commercially available or synthesized using conventional methods and can be used directly without further processing, and all instruments used in the examples are commercially available.
[0069] Example 1:
[0070] 1) Take 30 kg of fresh Chinese gudgeon (Uranoscopus chinensis) and separate the gills, skin, and flesh. The gills weigh approximately 1.5 kg, the skin approximately 3.2 kg, and the flesh approximately 18.0 kg. Rinse each tissue three times with deionized water to remove surface impurities and blood, and then store at 4°C for later use.
[0071] 2) Take 1.0 kg of fish gills, 2.0 kg of fish skin, and 5.0 kg of fish meat for defatting treatment. Add 95% (v / v) ethanol to each tissue at a material-to-liquid ratio of 1:8 (g:mL) and stir and extract at 35℃ for 2 hours. After filtration, repeat the defatting process once, and place the resulting tissue residue under ventilated conditions to evaporate the residual ethanol.
[0072] After defatting, the fish gills, skin, and flesh were added to distilled water and homogenized at a ratio of 1:6 (g:mL). The homogenates were homogenized at 12,000 rpm for 5 minutes using a high-speed tissue homogenizer to obtain gill homogenate, skin homogenate, and flesh homogenate.
[0073] The fish gill homogenate was enzymatically hydrolyzed using papain. The pH was adjusted to 6.8, and 3500 U / g of papain substrate was added. Enzymatic hydrolysis was carried out at 55°C for 4 hours.
[0074] The fish skin homogenate was hydrolyzed using a combination of collagenase and flavor protease. Collagenase at 2000 U / g substrate and flavor protease at 2500 U / g substrate were added, and hydrolysis was carried out at 50℃ for 6 hours.
[0075] The fish homogenate was hydrolyzed using a combination of trypsin and alkaline protease. 3000 U / g trypsin and 2000 U / g alkaline protease were added, and the mixture was hydrolyzed at 45°C for 5 hours.
[0076] 3) After enzymatic hydrolysis, each hydrolysate was heated at 95℃ for 12 min to inactivate the enzyme, and then rapidly cooled to room temperature. The solutions were then centrifuged at 10,000 rpm for 20 min at 4℃, and the supernatant was collected.
[0077] 4) The obtained supernatant was sequentially passed through 10kDa, 5kDa and 3kDa ultrafiltration membranes for fractional ultrafiltration, and the permeate with a molecular weight less than 3kDa was collected.
[0078] The permeate was loaded onto a Sephadex G-25 dextran gel chromatography column (90cm×1.5cm) and eluted with 20mmol / L Tris-HCl buffer (pH 7.4) at a flow rate of 1.0mL / min. The absorption peak was monitored at a wavelength of 220nm, and the active components were collected according to the elution curve.
[0079] 5) The active component was further purified by reversed-phase high-performance liquid chromatography (RP-HPLC). The chromatographic column was a C18 column (4.6 mm × 250 mm, 5 μm); mobile phase A was ultrapure water containing 0.1% trifluoroacetic acid; mobile phase B was acetonitrile containing 0.1% trifluoroacetic acid; the gradient elution program was as follows:
[0080] 0–5 min: 5% B;
[0081] 5–40 min: 5%–40% B;
[0082] 40–45 min: 40%–95% B;
[0083] 45–50 min: 95% B;
[0084] 50–55 min: 95%–5% B.
[0085] The flow rate was 1.0 mL / min, and the detection wavelength was 220 nm.
[0086] To further confirm the structures of each bioactive peptide, the target peaks purified by reversed-phase high-performance liquid chromatography (RP-HPLC) were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS / MS). After collecting each chromatographic peak, LC-MS / MS was used for identification. The primary mass spectrometry scan range was 100–1500 m / z, and the secondary mass spectrometry scan range was 50–1500 m / z. Amino acid sequences were resolved by b-ion and g-ion fragmentation. The analytical results are as follows: The characteristic mass-to-charge ratio peaks of each target component were obtained by primary mass spectrometry detection (…). Figure 9 Characteristic ion peaks with mass-to-charge ratios of 857.21, 651.74, 630.15, 830.46, and 813.27 were obtained for G1, P1, P2, M1, and M2, respectively. Further secondary mass spectrometry analysis was performed on the corresponding characteristic ions. Based on the mass difference between the b-ion and y-ion fragments and the relationship between the continuous fragments, the target peptides were sequenced, and the amino acid sequences of G1, P1, P2, M1, and M2 were confirmed as RLPGDFR, GEPGPRG, DGEPGPA, QNWPFR, and VQGDFPR, respectively.
[0087] Note: The aforementioned primary mass spectrometry characteristic ions are used for target component screening. The final confirmation of the active peptide amino acid sequence is based on the resolution results of secondary mass spectrometry fragment ions. Since mass spectrometry detection uses mass-to-charge ratio for characterization, and different ionization forms, terminal state, and adduct ion forms may produce different detection peaks, this application does not use the value of a single primary mass spectrometry peak as the sole basis for amino acid sequence determination. Instead, it uses a combination of primary mass spectrometry characteristic ions and secondary mass spectrometry fragment ions for comprehensive confirmation. Final results:
[0088] Fish gill-derived bioactive peptide G1 (SEQ ID NO.1);
[0089] Fish skin-derived bioactive peptide P1 (SEQ ID NO.2);
[0090] Fish skin-derived bioactive peptide P2 (SEQ ID NO.3);
[0091] Fish-derived bioactive peptide M1 (SEQ ID NO.4);
[0092] Fish-derived bioactive peptide M2 (SEQ ID NO.5).
[0093] 6) Mix the obtained active peptides evenly according to the mass ratio G1:P1:P2:M1:M2=1:3:3:2:2 to obtain the compound active peptides.
[0094] Maltodextrin was then added as an excipient, and the total mass ratio of the compounded active peptides to the maltodextrin was 1:4. After mixing evenly, the mixture was freeze-dried to obtain a fish-derived active peptide composition for antiplatelet therapy.
[0095] The structural identification and mass spectrometry characterization results of the active peptide in this embodiment are as follows: Figure 9-13 As shown, the specific explanation is as follows:
[0096] Figure 9 The images show the electrophoresis gel images of the active peptides and the primary mass spectra obtained by LC-MS / MS detection of the five active peptides. Each active peptide component shows a single clear band in the electrophoresis, and each peptide shows the main peak signal of the target molecular weight in the primary mass spectrum, indicating that the purified components have good purity.
[0097] Figure 10 This is a schematic diagram of the reversed-phase HPLC-MS analysis of active peptide G1. After separation by gel chromatography and reversed-phase high-performance liquid chromatography of the enzymatic hydrolysate derived from fish gills, a sharp elution peak was obtained, corresponding to active peptide G1.
[0098] Figure 11 This diagram illustrates the separation and purification of bioactive peptides P1 and P2. After separation by gel chromatography and reversed-phase high-performance liquid chromatography, two main chromatographic peaks were obtained from the enzymatic hydrolysate derived from fish skin, corresponding to bioactive peptides P1 and P2, respectively, indicating that the two bioactive peptides derived from fish skin can be effectively separated.
[0099] Figure 12 The diagram shows the separation and purification of active peptides M1 and M2. After separation by gel chromatography and reversed-phase high-performance liquid chromatography, two main chromatographic peaks were obtained from the fish meat-derived enzymatic hydrolysate, corresponding to active peptides M1 and M2, respectively, indicating that the separation effect of the two active peptides from fish meat was good.
[0100] Figure 13 This is the overall mass spectrometry characterization of the composition formed by blending five bioactive peptides in a ratio of 1:3:3:2:2. Because each bioactive peptide in the composition may form different charge states, adduct ions, and fragment ions during ionization, therefore... Figure 13 In addition to the characteristic ions corresponding to the target peptide, ion peaks that differ from those in the primary mass spectrometry of a single purified peptide may also appear. Figure 13 The mass spectrometry characteristics used to characterize the pentapeptide complex are not intended as a basis for determining the molecular structure and amino acid sequence of the five active peptides individually; the structure of the five active peptides is determined by the LC-MS / MS secondary mass spectrometry analysis results of their respective purified components.
[0101] Example 2:
[0102] Take 1.0 kg of gills, 2.0 kg of skin, and 5.0 kg of meat from the Chinese gudgeon, and clean and degrease them respectively.
[0103] Degreasing was performed using 95% ethanol at a material-to-liquid ratio of 1:5 (g:mL), at a treatment temperature of 25℃, and for a treatment time of 1 hour.
[0104] After defatting, distilled water was added separately for homogenization, with a material-to-liquid ratio of 1:5 (g:mL).
[0105] The fish gill homogenate was hydrolyzed using papain at a concentration of 3000 U / g substrate, pH 6.5, temperature 50℃, and hydrolysis time of 3 hours.
[0106] The fish skin homogenate was hydrolyzed using a combination of collagenase and flavor protease, with collagenase added at 1500 U / g substrate and flavor protease added at 2000 U / g substrate. The hydrolysis was carried out at 45℃ for 5 hours.
[0107] The fish homogenate was hydrolyzed using a combination of trypsin and alkaline protease, with trypsin added at a concentration of 2500 U / g substrate and alkaline protease added at a concentration of 1500 U / g substrate. The hydrolysis was carried out at 40℃ for 4 hours.
[0108] After enzymatic hydrolysis, the enzyme was inactivated at 95℃ for 10 minutes.
[0109] It was then centrifuged at 4°C and 10,000 rpm for 15 min.
[0110] The supernatant was sequentially treated with 10kDa, 5kDa and 3kDa ultrafiltration membranes to collect the fraction with a molecular weight less than 3kDa.
[0111] The sample was then purified using Sephadex G-25 gel chromatography and reversed-phase high-performance liquid chromatography, and identified using LC-MS / MS.
[0112] The active peptides shown in SEQ ID NO.1 to 5 were obtained.
[0113] Five active peptides were mixed evenly in a mass ratio of G1:P1:P2:M1:M2=1:2:2:1:1 to obtain a compound active peptide.
[0114] Maltodextrin was added as an excipient, and the mixture was freeze-dried to obtain a fish-derived active peptide composition for antiplatelet therapy.
[0115] Example 3:
[0116] Take 1.0 kg of gills, 2.0 kg of skin, and 5.0 kg of meat from the Chinese gudgeon.
[0117] Degreasing was performed using 95% ethanol at a material-to-liquid ratio of 1:10 (g:mL), at a treatment temperature of 45℃, and for a treatment time of 3 h.
[0118] After defatting, distilled water is added to homogenize the mixture, with a material-to-liquid ratio of 1:10 (g:mL).
[0119] Fish gills were hydrolyzed using papain at a concentration of 4000 U / g substrate, pH 7.0, temperature 60℃, and for 5 hours.
[0120] Fish skin was hydrolyzed using a combination of collagenase and flavor protease, with collagenase added at 2500 U / g substrate and flavor protease added at 3000 U / g substrate, at a temperature of 55℃ for 8 hours.
[0121] Fish meat was hydrolyzed using a combination of trypsin and alkaline protease, with trypsin added at a concentration of 3500 U / g substrate and alkaline protease added at a concentration of 2500 U / g substrate, at a temperature of 50℃ for 6 hours.
[0122] After enzymatic hydrolysis, the enzyme was inactivated at 95℃ for 15 minutes.
[0123] Then centrifuged at 4℃ and 10,000 rpm for 20 min.
[0124] The supernatant was subjected to ultrafiltration through 10kDa, 5kDa and 3kDa ultrafiltration membranes in sequence, and the fraction with a molecular weight less than 3kDa was collected.
[0125] Purification was performed using Sephadex G-25 gel chromatography and reversed-phase high-performance liquid chromatography, and identification was performed using LC-MS / MS.
[0126] The active peptides shown in SEQ ID NO.1 to 5 were obtained.
[0127] Five active peptides were mixed evenly in a mass ratio of G1:P1:P2:M1:M2=1:4:4:3:3 to obtain a compound active peptide.
[0128] Maltodextrin was added as an excipient, and the mixture was freeze-dried to obtain a fish-derived active peptide composition for antiplatelet therapy.
[0129] Example 4:
[0130] Active peptides G1, P1, P2, M1 and M2 were obtained according to the method in Example 1, and were mixed in a mass ratio of 1:3:3:2:2 to obtain a compound active peptide.
[0131] By weight, 30 parts of compound active peptide, 40 parts of microcrystalline cellulose, 20 parts of lactose, 5 parts of sodium carboxymethyl cellulose, 2 parts of magnesium stearate and 3 parts of silicon dioxide are mixed evenly, and then wet granulated, dried at 60°C, granulated and tableted to obtain the antiplatelet fish-derived active peptide composition (antiplatelet active peptide tablets).
[0132] Example 5:
[0133] The compound active peptides were obtained according to the method in Example 1.
[0134] By weight, 35 parts of compound active peptide, 35 parts of microcrystalline cellulose, 20 parts of mannitol, 5 parts of hydroxypropyl methylcellulose, 2 parts of magnesium stearate and 3 parts of silicon dioxide are mixed evenly and filled into No. 0 empty capsules to obtain the antiplatelet fish-derived active peptide composition (antiplatelet active peptide capsule).
[0135] Example 6:
[0136] The compound active peptides were obtained according to the method in Example 1.
[0137] By weight, 25 parts of compound active peptide, 45 parts of maltodextrin, 15 parts of lactose, 8 parts of gum arabic, 5 parts of polyvinylpyrrolidone and 2 parts of silicon dioxide are mixed evenly, and after granulation and drying, a fish-derived active peptide composition for antiplatelet use (antiplatelet active peptide granules) is obtained.
[0138] Example 7:
[0139] The compound active peptides were obtained according to the method in Example 1.
[0140] By weight, take 10 parts of compound active peptide, 5 parts of mannitol, 1 part of gum arabic, 0.5 parts of sodium citrate, 0.2 parts of vitamin C, 0.1 parts of potassium sorbate, and purified water to make up to 100 parts. Stir to dissolve, homogenize, filter, fill and sterilize to obtain the antiplatelet fish-derived active peptide composition (antiplatelet active peptide oral solution).
[0141] Example 8:
[0142] The compound active peptides were obtained according to the method in Example 1.
[0143] By weight, 40 parts of compound active peptide, 30 parts of mannitol, 10 parts of hydroxypropyl methylcellulose, 10 parts of polyvinylpyrrolidone and 10 parts of lactose were dissolved in purified water, sterile filtered and packaged, pre-frozen at -40℃ for 12 hours, and then vacuum freeze-dried for 24 hours to obtain the antiplatelet fish-derived active peptide composition (antiplatelet active peptide lyophilized powder).
[0144] Example 9:
[0145] The compound active peptides were obtained according to the method in Example 1.
[0146] By weight, 20 parts of compound active peptide, 50 parts of maltodextrin, 10 parts of gum arabic, 10 parts of lactose, 2 parts of vitamin C, 3 parts of citric acid and 5 parts of silicon dioxide are mixed evenly, and then granulated and dried in a fluidized bed to obtain a fish-derived active peptide composition for antiplatelet use (antiplatelet active peptide solid beverage).
[0147] Comparative Example 1:
[0148] Compared with Example 1, fish gill-derived active peptide G1 (SEQ ID NO.1) was not added. Instead, fish skin-derived active peptide P1, fish skin-derived active peptide P2, fish meat-derived active peptide M1, and fish meat-derived active peptide M2 were mixed in a mass ratio of 3:3:2:2. The rest of the preparation process and excipient composition were the same as in Example 1, and the composition of Comparative Example 1 was obtained.
[0149] Comparative Example 2:
[0150] Compared with Example 1, fish skin-derived active peptides P1 and P2 were not added. Instead, fish gill-derived active peptide G1, fish meat-derived active peptide M1, and fish meat-derived active peptide M2 were mixed in a mass ratio of 1:2:2. The remaining preparation process and excipient composition were the same as in Example 1, thus obtaining the composition of Comparative Example 2.
[0151] Comparative Example 3:
[0152] Compared with Example 1, fish meat-derived active peptides M1 and M2 were not added. Instead, fish gill-derived active peptide G1, fish skin-derived active peptide P1, and fish skin-derived active peptide P2 were mixed in a mass ratio of 1:3:3. The remaining preparation process and excipient composition were the same as in Example 1, thus obtaining the composition of Comparative Example 3.
[0153] Comparative Example 4:
[0154] Compared with Example 1, five active peptides G1, P1, P2, M1 and M2 were mixed in a mass ratio of 1:1:1:1:1, and the rest of the preparation process and excipient composition were the same as in Example 1 to obtain the composition of Comparative Example 4.
[0155] Experiments and Data
[0156] The performance of the compositions obtained in the examples and comparative examples was tested, as follows:
[0157] 1. Detection of ADP-induced platelet aggregation rate
[0158] Whole blood was collected from healthy SD rats and anticoagulated with 3.8% sodium citrate. Platelet-rich plasma (PRP) was obtained by centrifugation at 1000 rpm for 10 min. PRP was added to samples from the aspirin group, Example 1 group, Example 2 group, Example 3 group, and each comparative group, and incubated at 37℃ for 10 min. Subsequently, ADP at a final concentration of 10 μmol / L was added to induce platelet activation. Platelet aggregation was continuously monitored for 6 min using a platelet aggregator, and the maximum aggregation rate was recorded. A blank group (PRP) and a model group (PRP + ADP) were set up as controls. Subsequent experiments 2, 3, 7, and 8 were similarly set up.
[0159] The formula for calculating platelet aggregation inhibition rate is as follows:
[0160] .
[0161] See results Figure 1 According to Table 1 below, the samples of Examples 1-3 showed significant inhibitory effects on ADP-induced platelet aggregation, and the inhibitory effect of Example 1 was better than that of the aspirin group. The inhibition rates of Comparative Examples 1-4 and other samples with fewer than five active peptides were significantly lower than those of Examples 1-3, indicating that the five active peptides have a synergistic effect when combined in a specific ratio, which can significantly inhibit ADP-induced platelet activation and aggregation.
[0162] Table 1
[0163]
[0164] 2. PAC-1 flow cytometry detection
[0165] PRP was collected, and after processing each group of samples, ADP (10 μmol / L) was added for stimulation for 5 min. Then, FITC-labeled PAC-1 antibody was added, and the mixture was incubated in the dark for 20 min. The proportion of PAC-1 positive platelets was detected by flow cytometry to evaluate the GPIIb / IIIa receptor activation level.
[0166] See results Figure 2As shown in Table 2, the blank group consisted of platelets without ADP stimulation, whose PAC-1 positivity rate was at a low level, representing the basal activation level of platelet GPIIb / IIIa receptors. The model group, after ADP stimulation without any test sample, showed a significantly higher PAC-1 positivity rate than the blank group, indicating that ADP successfully induced platelet GPIIb / IIIa receptor activation. The PAC-1 positivity rates of Examples 1-3 were significantly lower than those of the model group, indicating that the sample from the examples effectively inhibited ADP-induced GPIIb / IIIa receptor activation. Example 1 showed the best inhibitory effect, superior to the aspirin group. The PAC-1 positivity rates of Comparative Examples 1-4 were higher than those of the examples, indicating that the five active peptides, when combined in a specific ratio, had a better inhibitory effect on GPIIb / IIIa receptor activation than other active peptide combinations and mixing ratios.
[0167] Table 2
[0168]
[0169] Note: The lower the PAC-1 positivity rate, the lower the degree of platelet activation.
[0170] 3. Detection of P-selectin (CD62P) expression
[0171] PRP was collected, and after pretreatment of each group of samples, ADP was added for stimulation for 5 min. PE-labeled CD62P antibody was added, and the mixture was incubated in the dark for 20 min. The positive expression rate of CD62P was detected by flow cytometry.
[0172] See results Figure 3 As shown in Table 3, the blank group consisted of platelets without ADP stimulation, whose CD62P positivity rate was at a low level, representing the basal release level of platelet α-granules. The model group, after ADP stimulation without any test sample, showed a significantly higher CD62P positivity rate than the blank group, indicating that ADP successfully induced the release of platelet α-granules. The CD62P positivity rates of Examples 1-3 were significantly lower than those of the model group, indicating that the sample from the examples could effectively inhibit ADP-induced release of platelet α-granules, with Example 1 showing the best inhibitory effect, superior to aspirin. The CD62P positivity rates of Comparative Examples 1-4 were higher than those of the examples, indicating that the inhibitory effect of the five active peptides combined in a specific ratio on the release of platelet α-granules was better than other combinations and mixing ratios of active peptides.
[0173] Table 3
[0174]
[0175] Note: CD62P expression level reflects the degree of platelet α-granule release; decreased expression indicates that platelet activation is inhibited.
[0176] 4. FeCl3-induced carotid artery thrombosis model
[0177] Male SD rats were randomly divided into a model group, an aspirin group, an example group, and a control group. All rats were administered the drug by gavage for 14 consecutive days, except for the model group which received no drug. After the last administration, the animals were anesthetized, the common carotid artery was isolated, and filter paper soaked in 10% FeCl3 solution was attached to the surface of the blood vessel for 3 minutes. The filter paper was removed and the animal was rinsed with physiological saline. Blood flow changes were monitored using Doppler flowmeter, and the occlusion time was recorded.
[0178] See results Figure 4 As shown in Table 4 below, the blood flow occlusion time in the model group was shorter, indicating that FeCl3 successfully induced carotid artery thrombosis. The complete blood flow occlusion time in Examples 1-3 was significantly longer than that in the model group, indicating that the samples in the examples have antithrombotic effects in vivo. Among them, the occlusion time in Example 1 was the longest and superior to that in the aspirin group. The blood flow occlusion time in Comparative Examples 1-4 was shorter than that in the examples, indicating that the in vivo antithrombotic effect of the five active peptides compounded in a specific ratio was better than that of other active peptide combinations and mixing ratios.
[0179] Table 4
[0180]
[0181] Note: The longer the blocking time, the better the antithrombotic effect.
[0182] 5. Coagulation function tests (PT / APTT / TT)
[0183] Male SD rats were randomly divided into a control group, an aspirin group, and an example group. All rats were administered the drug via gavage for 14 consecutive days, except for the control group which received no drug. Blood was collected from the abdominal aorta of each group and anticoagulated with 3.8% sodium citrate. Plasma was obtained by centrifugation at 3000 rpm for 10 min.
[0184] The coagulation analyzer was used for testing.
[0185] ①Prothrombin time (PT)
[0186] ②Activated partial thromboplastin time (APTT)
[0187] ③Thrombin time (TT) was used to compare the changes in indicators among the groups.
[0188] See results Figure 5 As shown in Table 5 below, there was no significant difference between the example group and the blank group, indicating that the sample in the example did not significantly affect the coagulation cascade reaction.
[0189] Table 5
[0190]
[0191] 6. Tail bleeding time detection
[0192] Male SD rats were randomly divided into a control group, an aspirin group, and an example group. All rats were administered the drug via gavage for 14 consecutive days, while the control group received no drug. A tail hemorrhage experiment was then performed on the rats: after anesthesia, the tail was cut approximately 3 mm from the tip, and the tail was immediately immersed in 37°C physiological saline. The time required from the onset of bleeding to complete hemostasis was recorded (a drop of blood was gently touched with filter paper every 15 seconds, without direct contact with the wound).
[0193] See results Figure 6 As shown in Table 6 below, the tail bleeding time of rats in the blank group represents the basic hemostatic ability under the untreated state; the tail bleeding time of the aspirin group was significantly longer than that of the blank group, indicating that aspirin increased the bleeding risk while exerting its antiplatelet effect; the tail bleeding time of Examples 1-3 was close to that of the blank group, indicating that the samples of the examples effectively inhibited platelet aggregation while having little impact on the body's normal hemostatic function and low bleeding risk.
[0194] Table 6
[0195]
[0196] Note: The shorter the bleeding time or the closer it is to that of the control group, the lower the risk of bleeding in the sample.
[0197] 7. Detection of PI3K / Akt signal pathway
[0198] PRP was collected, and after processing of each group of samples, ADP was added for stimulation for 5 min. Platelet pellet was collected, and total protein was extracted using RIPA lysis buffer. Western blotting was used to detect PI3K, p-PI3K, Akt, and p-Akt; grayscale analysis was performed using ImageJ software, and the p-PI3K / PI3K and p-Akt / Akt ratios were used to evaluate the activation level of the signaling pathway.
[0199] See results Figure 7 According to Table 7, the p-PI3K / PI3K and p-Akt / Akt ratios of the example group were significantly lower than those of the model group, indicating that it can suppress the downstream PI3K / Akt signal transduction of P2Y12.
[0200] Table 7
[0201]
[0202] 8. VASP phosphorylation detection
[0203] PRP was collected, and after processing of each group of samples, ADP stimulation was added to collect platelet protein samples. Western blotting was used to detect VASP and p-VASP (Ser157); the p-VASP / VASP ratio was calculated using ImageJ software.
[0204] See results Figure 8 As shown in Table 8, the p-VASP / VASP ratio in the blank group was at a baseline level. In the model group, this ratio was significantly lower than in the blank group after ADP stimulation. The p-VASP / VASP ratios in Examples 1-3 were all higher than those in the model group, indicating that the samples in these examples could inhibit P2Y12 receptor activity and restore intracellular cAMP signaling, verifying that the composition of this invention exerts its antiplatelet effect through the P2Y12-cAMP-VASP pathway. The p-VASP / VASP ratios in Comparative Examples 1-4 were all lower than those in the examples, indicating that the five active peptides, when combined in a specific ratio, had a better regulatory effect on the P2Y12-cAMP-VASP pathway than other combinations and mixing ratios of active peptides.
[0205] Table 8
[0206]
[0207] Note: Elevated p-VASP levels indicate that P2Y12 receptor activity is inhibited and intracellular cAMP signaling is restored.
[0208] 9. Detection of the effect on thrombin-induced platelet clot retraction
[0209] Experimental Methods: Whole blood was collected from healthy SD rats and anticoagulated with 3.8% sodium citrate (1:9). Platelet-rich plasma (PRP) was obtained by centrifugation at 1000 rpm for 10 min. The experiment was divided into three groups:
[0210] Blank group (normal control group): Take 400 μL of PRP and add 50 μL of physiological saline, without adding any activator.
[0211] Model group: 400 μL of PRP was added to 50 μL of normal saline, followed by the addition of thrombin at a final concentration of 0.2 U / mL to induce clot retraction.
[0212] The composition of the present invention is as follows: Take 400 μL of PRP, add 50 μL of the sample of Example 1 (final concentration of 4 mM), incubate for 10 min, and then add thrombin with a final concentration of 0.2 U / mL.
[0213] Each group of samples was placed in a transparent flat-bottomed glass test tube and incubated in a water bath at 37°C. The morphological changes of the blood clots in the test tubes were observed and photographed at 0 min, 10 min, 20 min, 30 min, 40 min, 50 min and 60 min after the addition of thrombin.
[0214] Experimental results are as follows Figure 14 As shown, the fish-derived active peptide composition of the present invention can block downstream signals by antagonizing the P2Y12 receptor, thereby strongly inhibiting thrombin-induced platelet clot retraction. Since clot retraction directly reflects the stability and volume compressibility of the thrombus, this result further strongly corroborates the excellent anti-platelet activation and anti-thrombotic effects of the composition of the present invention from the perspectives of fluid dynamics and spatial morphology.
[0215] The above description of the disclosed embodiments enables those skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A compound active peptide, characterized in that, It is composed of five bioactive peptides derived from different tissues of the Chinese gizzard, and the five bioactive peptides are as follows: The amino acid sequence is shown in SEQ ID NO.
1. Fish gill-derived bioactive peptide G1; The amino acid sequence is shown in SEQ ID NO.2 for fish skin-derived bioactive peptide P1; The amino acid sequence is shown in SEQ ID NO.3 for fish skin-derived bioactive peptide P2; The amino acid sequence of fish-derived bioactive peptide M1 is shown in SEQ ID NO.4; The amino acid sequence is shown in SEQ ID NO.
5. Fish-derived bioactive peptide M2.
2. The compound active peptide according to claim 1, characterized in that, The mass ratio of the five active peptides is 1:(2-4):(2-4):(1-3):(1-3).
3. The compound active peptide according to claim 2, characterized in that, The mass ratio of the five active peptides is 1:3:3:2:
2.
4. A method for preparing the compound active peptide according to any one of claims 1 to 3, characterized in that, Includes the following steps: 1) The gills, skin, and flesh of the Chinese mackerel are pre-treated by cleaning, defatting, and crushing. 2) The pretreated fish gills, fish skin and fish meat were enzymatically hydrolyzed separately to obtain fish gill hydrolysate, fish skin hydrolysate and fish meat hydrolysate; 3) Heat the three enzymatic hydrolysates to inactivate the enzymes, centrifuge, and collect the corresponding supernatants respectively; 4) Perform ultrafiltration on each of the supernatants obtained in step 3), and then collect the permeate with a molecular weight of less than 3 kDa. 5) The permeate obtained in step 4) is purified by chromatography. The components are collected according to the chromatographic elution peaks and identified by liquid chromatography-tandem mass spectrometry as active peptides G1, P1, P2, M1 and M2 with amino acid sequences as shown in SEQ ID NO.1 to 5. 6) Mix the five active peptides collected in step 5) in proportion to obtain the compound active peptide.
5. The method for preparing the compound active peptide according to claim 4, characterized in that, In step 2): The fish gills were hydrolyzed using papain. Fish skin is hydrolyzed using a combination of collagenase and flavor protease; The fish meat is hydrolyzed using a combination of trypsin and alkaline protease.
6. The method for preparing the compound active peptide according to claim 4, characterized in that, The ultrafiltration described in step 4) is a graded ultrafiltration process using ultrafiltration membranes with molecular weight cutoffs of 10 kDa, 5 kDa, and 3 kDa in sequence.
7. The method for preparing the compound active peptide according to claim 4, characterized in that, The chromatographic purification described in step 5) includes gel chromatography and reversed-phase high-performance liquid chromatography.
8. A fish-derived active peptide composition for antiplatelet therapy, characterized in that, It is composed of an active ingredient and pharmaceutically or food-grade acceptable excipients; the active ingredient is the compound active peptide according to any one of claims 1 to 3; the excipients are selected from one or more of maltodextrin, microcrystalline cellulose, hydroxypropyl methylcellulose, lactose, mannitol, gum arabic, polyvinylpyrrolidone, sodium carboxymethyl cellulose, magnesium stearate, silicon dioxide, sodium citrate, vitamin C, potassium sorbate, citric acid, and water.
9. The antiplatelet fish-derived active peptide composition according to claim 8, characterized in that, Its dosage form is one of the following: tablets, capsules, granules, oral liquid, lyophilized powder, or solid beverage.
10. The use of the compound active peptide as described in any one of claims 1 to 3 or the antiplatelet fish-derived active peptide composition as described in any one of claims 8 to 9 in the preparation of a drug or functional food for inhibiting platelet aggregation and / or preventing thrombosis.
